SG11201805066RA - Alkyl dihydroquinoline sulfonamide compounds - Google Patents
Alkyl dihydroquinoline sulfonamide compoundsInfo
- Publication number
- SG11201805066RA SG11201805066RA SG11201805066RA SG11201805066RA SG11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA SG 11201805066R A SG11201805066R A SG 11201805066RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- street
- amgen
- compounds
- massachusetts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
asto applicant's entitlement to apply for and be granted a patent (Rule .1700) ished: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (51) International Patent Classification: CO7D 403/12 (2006.01) A61K 31/4704 (2006.01) CO7D 413/12 (2006.01) A61P 29/00 (2006.01) (21) International Application Number: PCT/US2016/067617 (22) International Filing Date: 19 December 2016 (19.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/269,518 18 December 2015 (18.12.2015) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). arations under Rule 4.17: (72) Inventors: WEISS, Matthew; 99 Revere Street, Boston, Massachusetts 02114 (US). MILGRAM, Benjamin C; 36 Decl Ash Street, Apt. 101, Cambridge, Massachusetts 02138 (US). MARX, Isaac E.; 7 Michael Street, Arlington, Mas- sachusetts 02474 (US). DINEEN, Thomas; 36 Waterhouse Street, Somerville, Massachusetts 02144 (US). Publ (74) Agent: LEMOINE, Elsa; Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, W O 20 17 / 10687 1 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/106871 Al 22 June 2017 (22.06.2017) WIPO I PCT (54) Title: ALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS (I) R 5c R 5 d (57) : The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are in- hibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions con- taining compounds of the present invention. 111111111111110111010101111101011111011101011011111111101111101111111110111111
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269518P | 2015-12-18 | 2015-12-18 | |
| PCT/US2016/067617 WO2017106871A1 (en) | 2015-12-18 | 2016-12-19 | Alkyl dihydroquinoline sulfonamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805066RA true SG11201805066RA (en) | 2018-07-30 |
Family
ID=57758767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805066RA SG11201805066RA (en) | 2015-12-18 | 2016-12-19 | Alkyl dihydroquinoline sulfonamide compounds |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10383866B2 (en) |
| EP (1) | EP3390392B1 (en) |
| JP (1) | JP6903663B2 (en) |
| KR (1) | KR20180094946A (en) |
| CN (2) | CN119119017A (en) |
| AU (1) | AU2016369652B2 (en) |
| CA (1) | CA3008484C (en) |
| CL (1) | CL2018001631A1 (en) |
| CO (1) | CO2018007436A2 (en) |
| CR (1) | CR20180368A (en) |
| EA (1) | EA038286B1 (en) |
| IL (1) | IL259918B (en) |
| MA (1) | MA44065A (en) |
| MX (1) | MX377032B (en) |
| MY (1) | MY197595A (en) |
| NZ (1) | NZ743377A (en) |
| PE (1) | PE20181328A1 (en) |
| PH (1) | PH12018501285A1 (en) |
| SG (1) | SG11201805066RA (en) |
| TN (1) | TN2018000214A1 (en) |
| UA (1) | UA122913C2 (en) |
| WO (1) | WO2017106871A1 (en) |
| ZA (1) | ZA201804033B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI773657B (en) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| MX2022015857A (en) | 2020-06-10 | 2023-01-24 | Amgen Inc | Heteroalkyl dihydroquinoline sulfonamide compounds. |
| JP2021195368A (en) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | Cyclobutyldihydroquinoline sulfonamide compound |
| JP2021195367A (en) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | Cyclopropyldihydroquinoline sulfonamide compound |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CA2844799A1 (en) * | 2011-08-17 | 2013-02-21 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| EP2788332A1 (en) * | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| WO2013134518A1 (en) | 2012-03-09 | 2013-09-12 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| US9776995B2 (en) * | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-12-19 PE PE2018001136A patent/PE20181328A1/en unknown
- 2016-12-19 KR KR1020187019086A patent/KR20180094946A/en active Pending
- 2016-12-19 CA CA3008484A patent/CA3008484C/en active Active
- 2016-12-19 MX MX2018007432A patent/MX377032B/en active IP Right Grant
- 2016-12-19 NZ NZ743377A patent/NZ743377A/en unknown
- 2016-12-19 EA EA201891319A patent/EA038286B1/en unknown
- 2016-12-19 CR CR20180368A patent/CR20180368A/en unknown
- 2016-12-19 TN TNP/2018/000214A patent/TN2018000214A1/en unknown
- 2016-12-19 MA MA044065A patent/MA44065A/en unknown
- 2016-12-19 CN CN202411119481.8A patent/CN119119017A/en active Pending
- 2016-12-19 EP EP16823447.4A patent/EP3390392B1/en active Active
- 2016-12-19 SG SG11201805066RA patent/SG11201805066RA/en unknown
- 2016-12-19 US US16/062,606 patent/US10383866B2/en active Active
- 2016-12-19 AU AU2016369652A patent/AU2016369652B2/en active Active
- 2016-12-19 MY MYPI2018000912A patent/MY197595A/en unknown
- 2016-12-19 CN CN201680074274.2A patent/CN108602804A/en active Pending
- 2016-12-19 UA UAA201806895A patent/UA122913C2/en unknown
- 2016-12-19 WO PCT/US2016/067617 patent/WO2017106871A1/en active Application Filing
- 2016-12-19 JP JP2018531483A patent/JP6903663B2/en active Active
-
2018
- 2018-06-10 IL IL259918A patent/IL259918B/en active IP Right Grant
- 2018-06-14 PH PH12018501285A patent/PH12018501285A1/en unknown
- 2018-06-15 ZA ZA2018/04033A patent/ZA201804033B/en unknown
- 2018-06-15 CL CL2018001631A patent/CL2018001631A1/en unknown
- 2018-07-17 CO CONC2018/0007436A patent/CO2018007436A2/en unknown
-
2019
- 2019-07-12 US US16/510,816 patent/US20200009129A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ743377A (en) | 2022-05-27 |
| WO2017106871A1 (en) | 2017-06-22 |
| EA038286B1 (en) | 2021-08-04 |
| PE20181328A1 (en) | 2018-08-20 |
| IL259918A (en) | 2018-07-31 |
| CA3008484C (en) | 2023-10-17 |
| BR112018012298A2 (en) | 2018-12-04 |
| UA122913C2 (en) | 2021-01-20 |
| MA44065A (en) | 2021-05-26 |
| PH12018501285A1 (en) | 2019-02-04 |
| JP2019504016A (en) | 2019-02-14 |
| EP3390392B1 (en) | 2021-10-06 |
| US20200009129A1 (en) | 2020-01-09 |
| ZA201804033B (en) | 2019-04-24 |
| JP6903663B2 (en) | 2021-07-14 |
| CO2018007436A2 (en) | 2018-07-19 |
| US20180369227A1 (en) | 2018-12-27 |
| EP3390392A1 (en) | 2018-10-24 |
| IL259918B (en) | 2020-06-30 |
| MX377032B (en) | 2025-03-07 |
| CR20180368A (en) | 2018-09-28 |
| AU2016369652A1 (en) | 2018-06-28 |
| KR20180094946A (en) | 2018-08-24 |
| EA201891319A1 (en) | 2018-11-30 |
| MX2018007432A (en) | 2018-09-21 |
| CA3008484A1 (en) | 2017-06-22 |
| AU2016369652B2 (en) | 2020-10-22 |
| CN119119017A (en) | 2024-12-13 |
| US10383866B2 (en) | 2019-08-20 |
| MY197595A (en) | 2023-06-27 |
| CL2018001631A1 (en) | 2018-09-28 |
| CN108602804A (en) | 2018-09-28 |
| TN2018000214A1 (en) | 2019-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201805066RA (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201810561YA (en) | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression |